Siraj M. Ali

48.9k total citations · 7 hit papers
381 papers, 27.2k citations indexed

About

Siraj M. Ali is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Siraj M. Ali has authored 381 papers receiving a total of 27.2k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Pulmonary and Respiratory Medicine, 177 papers in Oncology and 149 papers in Cancer Research. Recurrent topics in Siraj M. Ali's work include Cancer Genomics and Diagnostics (132 papers), Lung Cancer Treatments and Mutations (108 papers) and Genetic factors in colorectal cancer (41 papers). Siraj M. Ali is often cited by papers focused on Cancer Genomics and Diagnostics (132 papers), Lung Cancer Treatments and Mutations (108 papers) and Genetic factors in colorectal cancer (41 papers). Siraj M. Ali collaborates with scholars based in United States, Italy and South Korea. Siraj M. Ali's co-authors include David M. Sabatini, Dos D. Sarbassov, David A. Guertin, Paul Tempst, Hediye Erdjument‐Bromage, Do‐Hyung Kim, Robert Latek, Jeffrey S. Ross, Vincent A. Miller and Alexa B. Schrock and has published in prestigious journals such as Science, Cell and Journal of Biological Chemistry.

In The Last Decade

Siraj M. Ali

367 papers receiving 26.9k citations

Hit Papers

Phosphorylation and Regul... 2002 2026 2010 2018 2005 2002 2004 2006 2005 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex
    2005 5.2k citations Dos D. Sarbassov, David A. Guertin et al. Science profile →
  2. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery
    2002 2.4k citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
  3. Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
    2004 2.1k citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
  4. Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
    2006 2.1k citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
  5. Growing roles for the mTOR pathway
    2005 1.3k citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
  6. GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR
    2003 772 citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
  7. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
    2019 441 citations Alexa B. Schrock, Dexter X. Jin et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Siraj M. Ali United States 68 15.8k 8.8k 6.6k 4.7k 3.5k 381 27.2k
Erik Larsson Sweden 56 21.9k 1.4× 8.3k 0.9× 6.9k 1.0× 9.7k 2.0× 2.4k 0.7× 208 34.1k
Christine A. Iacobuzio–Donahue United States 87 13.3k 0.8× 17.3k 2.0× 4.3k 0.7× 9.1k 1.9× 4.8k 1.4× 285 29.5k
Joseph R. Testa United States 83 14.1k 0.9× 5.4k 0.6× 5.9k 0.9× 3.9k 0.8× 1.5k 0.4× 347 24.5k
William L. Gerald United States 93 18.9k 1.2× 12.0k 1.4× 12.1k 1.8× 8.8k 1.8× 1.9k 0.5× 241 36.1k
Nabeel Bardeesy United States 84 19.1k 1.2× 12.0k 1.4× 2.3k 0.4× 7.4k 1.6× 5.1k 1.5× 182 30.8k
Jeffrey A. Engelman United States 91 21.3k 1.3× 16.0k 1.8× 13.8k 2.1× 6.2k 1.3× 1.8k 0.5× 187 36.0k
Olli Kallioniemi Finland 99 20.2k 1.3× 9.7k 1.1× 7.4k 1.1× 11.3k 2.4× 2.7k 0.8× 428 36.3k
Michael J. Birrer United States 83 13.5k 0.9× 9.5k 1.1× 2.5k 0.4× 5.1k 1.1× 1.8k 0.5× 434 25.4k
Kenneth Aldape United States 90 13.1k 0.8× 6.6k 0.8× 4.8k 0.7× 8.1k 1.7× 1.1k 0.3× 369 27.8k
Sabina Signoretti United States 69 11.5k 0.7× 6.9k 0.8× 8.2k 1.3× 6.2k 1.3× 2.1k 0.6× 296 20.4k

Countries citing papers authored by Siraj M. Ali

Since Specialization
Citations

This map shows the geographic impact of Siraj M. Ali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siraj M. Ali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siraj M. Ali more than expected).

Fields of papers citing papers by Siraj M. Ali

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siraj M. Ali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siraj M. Ali. The network helps show where Siraj M. Ali may publish in the future.

Co-authorship network of co-authors of Siraj M. Ali

This figure shows the co-authorship network connecting the top 25 collaborators of Siraj M. Ali. A scholar is included among the top collaborators of Siraj M. Ali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siraj M. Ali. Siraj M. Ali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Madison, Russell W., Sumati Gupta, Yasir Y. Elamin, et al.. (2020). Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. British Journal of Urology. 125(5). 739–746. 11 indexed citations
2.
Brown, Benjamin P., Yunkai Zhang, David Westover, et al.. (2019). On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Clinical Cancer Research. 25(11). 3341–3351. 76 indexed citations
3.
Serebriiskii, Ilya G., Caitlin Connelly, Garrett M. Frampton, et al.. (2019). Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nature Communications. 10(1). 3722–3722. 149 indexed citations
4.
Sokol, Ethan, Dexter X. Jin, Ahmed Basudan, et al.. (2018). Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Annals of Oncology. 30(1). 115–123. 58 indexed citations
5.
Schrock, Alexa B., Dean C. Pavlick, Samuel J. Klempner, et al.. (2018). Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research. 24(8). 1881–1890. 54 indexed citations
6.
Bhangoo, Munveer S., et al.. (2018). Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma. The Oncologist. 23(5). 518–523. 45 indexed citations
7.
Ali, Siraj M., Ming Yao, Jicheng Yao, et al.. (2017). Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. Cancer. 123(18). 3628–3637. 36 indexed citations
8.
Elvin, Julia A., Laurie M. Gay, Joseph Shuluk, et al.. (2017). Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration. The Oncologist. 22(4). 416–421. 41 indexed citations
9.
Johnson, Douglas B., Zachary R. Chalmers, Garrett M. Frampton, et al.. (2017). BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. Pigment Cell & Melanoma Research. 31(3). 432–436. 28 indexed citations
10.
Pavlick, Dean C., Jon Chung, Julia A. Elvin, et al.. (2017). Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types. Annals of Oncology. 28. v595–v595. 4 indexed citations
11.
Schwab, Richard B., María Koehler, Siraj M. Ali, & Brion W. Murray. (2016). Genomic profiling and treatment of HER2+, ER+, PgR+ “triple positive” breast cancer: A case report and literature review. Cancer Treatment and Research Communications. 9. 27–31. 2 indexed citations
12.
Yakirevich, Evgeny, Murray B. Resnick, Shamlal Mangray, et al.. (2016). Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. Clinical Cancer Research. 22(15). 3831–3840. 88 indexed citations
13.
Gallant, Jean‐Nicolas, Jonathan H. Sheehan, Timothy M. Shaver, et al.. (2015). EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discovery. 5(11). 1155–1163. 81 indexed citations
14.
Wang, Kai, Adrienne Johnson, Siraj M. Ali, et al.. (2015). Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. The Oncologist. 20(10). 1132–1139. 75 indexed citations
15.
Elvin, Julia A., Rachel M. Squillace, Vincent A. Miller, et al.. (2015). A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. Lung Cancer. 92. 19–21. 24 indexed citations
16.
Chmielecki, Juliann, Katherine E. Hutchinson, Garrett M. Frampton, et al.. (2014). Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes. Cancer Discovery. 4(12). 1398–1405. 126 indexed citations
17.
Chiron, David, Maurizio Di Liberto, Peter Martin, et al.. (2014). Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma. Cancer Discovery. 4(9). 1022–1035. 204 indexed citations
18.
Chmielecki, Juliann, Jeffrey S. Ross, Kai Wang, et al.. (2014). Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin. The Oncologist. 20(1). 7–12. 75 indexed citations
19.
Ross, Jeffrey S., Kai Wang, Christine E. Sheehan, et al.. (2013). Relapsed Classic E-Cadherin ( CDH1 )–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 ( ERBB2 ) Gene Mutations. Clinical Cancer Research. 19(10). 2668–2676. 96 indexed citations
20.
Sarbassov, Dos D., David A. Guertin, Siraj M. Ali, & David M. Sabatini. (2005). Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex. Science. 307(5712). 1098–1101. 5211 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erik Larsson Breakdown of academic impact, for papers by Christine A. Iacobuzio–Donahue Breakdown of academic impact, for papers by Joseph R. Testa Breakdown of academic impact, for papers by William L. Gerald Breakdown of academic impact, for papers by Nabeel Bardeesy Breakdown of academic impact, for papers by Jeffrey A. Engelman Breakdown of academic impact, for papers by Olli Kallioniemi Breakdown of academic impact, for papers by Michael J. Birrer Breakdown of academic impact, for papers by Kenneth Aldape Breakdown of academic impact, for papers by Sabina Signoretti
Rankless by CCL
2026